Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging.
Magnetic resonance imaging provides a method of visualizing multiple sclerosis plaques, but the age and activity of these plaques cannot be determined with routine magnetic resonance images. Gadolinium DTPA is a paramagnetic contrast agent that does not cross an intact blood-brain barrier. We studied 16 patients with multiple sclerosis, using magnetic resonance imaging, gadolinium-enhanced magnetic resonance imaging, and computed tomographic scans. Gadolinium enhancement of multiple sclerosis plaques correlated with the clinical activity of the disease and corresponded anatomically with the symptoms and signs. We conclude that gadolinium enhancement of magnetic resonance images is a promising tool in the investigation of multiple sclerosis lesions and that it may provide a method for objective follow-up in clinical trails.
D000328:Adult; D000368:Aged; D001921:Brain / Q000473:pathology*; D003287:Contrast Media; D004338:Drug Combinations / Q000009:adverse effects; D005260:Female; D005682:Gadolinium / Q000009:adverse effects; D019786:Gadolinium DTPA; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008536:Meglumine / Q000009:adverse effects; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000473:pathology; D009942:Organometallic Compounds / Q000009:adverse effects; D004369:Pentetic Acid / Q000009:adverse effects; D013012:Sorbitol / Q000031:analogs & derivatives*; D014057:Tomography, X-Ray Computed
D003287:Contrast Media; D004338:Drug Combinations; D009942:Organometallic Compounds; D013012:Sorbitol; D008536:Meglumine; D004369:Pentetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA